Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Acarbose/Metformin FDC vs Loose Combination in Healthy Chinese Subjects
NCT04065581Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of acarbose and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bayer. Primary endpoints: Maximum Serum Glucose Concentration Ratio at Day 1, Area Under the Serum Glucose Concentration-Time Curve Ratio at Day 1 and 2 more. Started Oct 2019; status: completed.
02
Drugs
acarboseliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04065581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065581.